Results 101 to 110 of about 1,554 (191)

Rezatapopt and the Return of Targetable p53. [PDF]

MedComm (2020)
Luo Y, El-Osta A.
europepmc   +1 more source

Correction: Overcoming chemoresistance in esophageal cancer with synergistic strategies. [PDF]

Front Immunol
Gao C, Zhang T, Li G, Zhang W, Chen H, Li D, Xu J, Li M, Wang R, Xing Y, Zhan J, Ren Z, Xue X, Liang W, Sun X, Zhang X, Liang X, Zhan H, Zhang Z, Chu X.   +19 more
europepmc   +1 more source

Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators. [PDF]

Cancer Discov
Fece de la Cruz F, Varkaris A, Patel PS, Kushner EW, Morales-Giron AA, Lee SS, Singh A, Kim CT, Norden BL, Ehnstrom S, Riedl JM, Curtis JM, Barnes H, Kehlmann AM, Chevalier NJ, Okuma HS, Patel M, Wirth LJ, Connell B, Nugent F, Pappas L, Lau K, Juric D, Hopkins JL, Guiley KZ, Shokat KM, Gulhan DC, Parikh AR, Corcoran RB.   +28 more
europepmc   +1 more source

Fragility of precision: resistance to mutant p53 reactivation. [PDF]

Signal Transduct Target Ther
Joerger AC, Stiewe T.
europepmc   +1 more source

Novel p53 reactivators that are synergistic with olaparib for the treatment of gynecologic cancers with mutant p53. [PDF]

Transl Oncol
Smith LE, Padilla JL, Licor A, Steinkamp MP, Lagutina IV, Guo Y, Devor EJ, Pankratz VS, Sallmyr A, Oyebamiji OM, Choe JY, Williams GL, Leslie KK.   +12 more
europepmc   +1 more source

Restoration of the Tumor Suppressor Function of Y220C-Mutant p53 by Rezatapopt, a Small-Molecule Reactivator. [PDF]

Cancer Discov
Puzio-Kuter AM, Xu L, McBrayer MK, Dominique R, Li HH, Fahr BJ, Brown AM, Wiebesiek AE, Russo BM, Mulligan CL, Yang H, Battaglia J, Robell KA, Thomas DH, Huang KS, Solovyov A, Greenbaum BD, Oliner JD, Davis TW, Dumble ML, Johnson ML, Xiong S, Yang P, Lozano G, Fellous MM, Vu BT, Schram AM, Levine AJ, Poyurovsky MV.   +28 more
europepmc   +1 more source

PYNNACLE phase II clinical trial protocol: rezatapopt (PC14586) monotherapy in advanced or metastatic solid tumors with a <i>TP53</i> Y220C mutation. [PDF]

Future Oncol
Schram AM, Fellous M, LeDuke K, Schmid A, Dumbrava EE.   +4 more
europepmc   +1 more source

Fundamentals and emerging frontiers in p53-targeted drug development. [PDF]

Biochem Biophys Rep
Long HD, Zhang N, Wang WE, Ma YS, Liu FX, Chen ZY, Lu CN, Wang XF, Han N, Cai YF, Yang C, Tang XM, Yu H, Jiang H, Fu D, Chu KJ, Wu WG.   +16 more
europepmc   +1 more source

Reactive syringofibroadenoma

Indian Journal of Dermatology, Venereology and Leprology, 2020
Piyush, Kumar, Anupam, Das, P C, Das
openaire   +2 more sources

Ferroptosis in gastrointestinal stromal tumors. [PDF]

J Gastrointest Oncol
Jenke R, Aigner A.
europepmc   +1 more source